Cargando…

Chemotherapy exacerbates the survival paradox of colon cancer: a propensity score matching analysis

BACKGROUND: Colon cancer is one of the most common tumor diseases in the world. Currently, clinicians usually evaluate the survival and prognosis of patients according to their tumor-node-metastasis (TNM) stage. However, current studies have found that there is a certain survival paradox in TNM stag...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Mengxiang, Zhou, Zhongyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834597/
https://www.ncbi.nlm.nih.gov/pubmed/36644182
http://dx.doi.org/10.21037/tcr-22-1630
_version_ 1784868496589455360
author Tian, Mengxiang
Zhou, Zhongyi
author_facet Tian, Mengxiang
Zhou, Zhongyi
author_sort Tian, Mengxiang
collection PubMed
description BACKGROUND: Colon cancer is one of the most common tumor diseases in the world. Currently, clinicians usually evaluate the survival and prognosis of patients according to their tumor-node-metastasis (TNM) stage. However, current studies have found that there is a certain survival paradox in TNM staging. METHODS: In the Surveillance, Epidemiology, and End Results (SEER) database, patients diagnosed with colon cancer by surgical pathology from 2004 to 2011 were selected for analysis of 5-year overall survival (OS). Propensity score matching (PSM) was performed to analyze the difference in survival between different stages and the effect of chemotherapy on prognosis. RESULTS: The OS of stage IIIA colon cancer sufferers was significantly superior to stage IIB/IIC and separate stage IIB or IIC colon cancer patients before and after PSM analysis (P<0.05 for all). Moreover, the difference in survival was more significant when stage IIB/IIC patients were compared with stage IIIA patients with chemotherapy. CONCLUSIONS: The survival paradox existed both in all stage IIB/IIC patients, or individual stage IIB or IIC patients compared with stage IIIA sufferers, and the survival paradox between stage IIIA and stage IIC was more obvious. Moreover, chemotherapy had a positive effect on the prognosis of patients with stage IIIA, IIC and IIB in this study. Chemotherapy exacerbates the survival paradox of colon cancer, even if it is not the cause of the survival paradox.
format Online
Article
Text
id pubmed-9834597
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-98345972023-01-13 Chemotherapy exacerbates the survival paradox of colon cancer: a propensity score matching analysis Tian, Mengxiang Zhou, Zhongyi Transl Cancer Res Original Article BACKGROUND: Colon cancer is one of the most common tumor diseases in the world. Currently, clinicians usually evaluate the survival and prognosis of patients according to their tumor-node-metastasis (TNM) stage. However, current studies have found that there is a certain survival paradox in TNM staging. METHODS: In the Surveillance, Epidemiology, and End Results (SEER) database, patients diagnosed with colon cancer by surgical pathology from 2004 to 2011 were selected for analysis of 5-year overall survival (OS). Propensity score matching (PSM) was performed to analyze the difference in survival between different stages and the effect of chemotherapy on prognosis. RESULTS: The OS of stage IIIA colon cancer sufferers was significantly superior to stage IIB/IIC and separate stage IIB or IIC colon cancer patients before and after PSM analysis (P<0.05 for all). Moreover, the difference in survival was more significant when stage IIB/IIC patients were compared with stage IIIA patients with chemotherapy. CONCLUSIONS: The survival paradox existed both in all stage IIB/IIC patients, or individual stage IIB or IIC patients compared with stage IIIA sufferers, and the survival paradox between stage IIIA and stage IIC was more obvious. Moreover, chemotherapy had a positive effect on the prognosis of patients with stage IIIA, IIC and IIB in this study. Chemotherapy exacerbates the survival paradox of colon cancer, even if it is not the cause of the survival paradox. AME Publishing Company 2022-12 /pmc/articles/PMC9834597/ /pubmed/36644182 http://dx.doi.org/10.21037/tcr-22-1630 Text en 2022 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Tian, Mengxiang
Zhou, Zhongyi
Chemotherapy exacerbates the survival paradox of colon cancer: a propensity score matching analysis
title Chemotherapy exacerbates the survival paradox of colon cancer: a propensity score matching analysis
title_full Chemotherapy exacerbates the survival paradox of colon cancer: a propensity score matching analysis
title_fullStr Chemotherapy exacerbates the survival paradox of colon cancer: a propensity score matching analysis
title_full_unstemmed Chemotherapy exacerbates the survival paradox of colon cancer: a propensity score matching analysis
title_short Chemotherapy exacerbates the survival paradox of colon cancer: a propensity score matching analysis
title_sort chemotherapy exacerbates the survival paradox of colon cancer: a propensity score matching analysis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834597/
https://www.ncbi.nlm.nih.gov/pubmed/36644182
http://dx.doi.org/10.21037/tcr-22-1630
work_keys_str_mv AT tianmengxiang chemotherapyexacerbatesthesurvivalparadoxofcoloncancerapropensityscorematchinganalysis
AT zhouzhongyi chemotherapyexacerbatesthesurvivalparadoxofcoloncancerapropensityscorematchinganalysis